New section

New section

More people are surviving cancer. What’s next?

Ross McKinney Jr., MD , Chief Scientific Officer
February 4, 2020

Continued advancements in medical research have revolutionized treatments in the last few decades. Further progress will depend on sustained funding and collaboration.

New section

New section

Editor’s note: This column originally appeared in BRINK News on February 4, 2020, World Cancer Day.

Last month, the American Cancer Society announced that 2017, the latest year for which data is available, saw the sharpest one-year drop in the U.S. cancer death rate ever recorded.

Advances in cancer therapy and treatment, as well as prevention efforts, are pushing down cancer mortality rates and saving millions of lives — 2.9 million in the United States since 1991 – even as diagnoses continue to rise. Indeed, an estimated 11 million more people worldwide will be diagnosed with cancer between now and 2040. In the United States alone, there will be roughly 1.8 million new cases of cancer this year, with over 16,000 of those in children.

But a cancer diagnosis is looking less like a death sentence, courtesy of the continued advances in medical research. To understand where we’re headed in cancer treatment, it’s important to acknowledge what got us to this point.

The Cancer Treatment Revolution

For years, three options existed for patients with cancer: surgery, chemotherapy, or radiation. The early 2000s saw the introduction of targeted therapies, which block genes and proteins that drive cancer growth and include nivolumab (Opdivo) and pembrolizumab (Keytruda) for lung cancer. At the same time, scientists were working on developing immunotherapies that use a heightened version of the patient’s own immune cells to fight cancer, reducing incidence and tumor size and enabling other treatments, including radiation, chemotherapy, and surgery, to be more effective.

The development of these targeted therapies and immunotherapies was the result of sustained, long-term research and collaboration among government agencies, scientists, academia, and industry.

With regard to immunotherapies, the revolution in treatment began in the 1960s, when researchers made two breakthroughs that laid the groundwork for future investigation: the discovery that the thymus is involved in cellular immunity and the recognition of the role B- and T-cells play in how the body fights infections and other diseases. Much of this work would lead to the development of the drug Rituximab, the first treatment to specifically target a surface protein found on cancer cells, which was approved by the U.S. Food and Drug Administration (FDA) in 1997 to treat certain types of lymphoma.

Throughout the 1980s and 1990s, American researchers, many of them at medical schools and teaching hospitals, began experimenting with genetically engineered T-cells, referred to as CAR T-cells, as a new way to fight cancer. In trials of CAR T-cell therapy — some operated with the aid of the NIH — researchers showed remarkable results in treating some forms of leukemia. In 2012, clinicians at the Children’s Hospital of Philadelphia reported nearly 90% of children and adolescents with a specific form of leukemia in a government-funded clinical trial had a complete and rapid response. In 2014, the FDA gave treatment for certain types of cancer using CAR T-cells a “Breakthrough Designation.”

The Treatment of Tomorrow

All of these treatments still have their limitations. Targeted therapies can impact other enzyme systems while attacking cancer cells, causing side effects. In some cases, CAR T-cell treatment can produce a toxic inflammatory response — known as a cytokine storm — by killing cells quickly. On the positive side, cytokine storms can be treated, and physicians are improving their ability to do so.

The biggest limitations of these treatments, though, is the range of cancers for which these new treatments are effective and their cost. So far, CAR T-cell therapy is only approved for types of blood cancers, such as leukemias and lymphomas, and can cost more than $1 million per patient in the United States.

The future of cancer treatment will depend on how effectively scientists can identify susceptible weak links toward which directed therapies can be aimed; how effectively early diagnoses can be made; and whether governments can manage the extreme costs of some treatments. Will we develop immunotherapies or advances in CAR T-cell treatment that can be used on solid tumor cancers? How will we advance diagnosis so that cancers are caught earlier, when they are likely more treatable? How will these treatments be paid for, and will their costs decrease?

Research is being done in labs across the world, continuing the partnerships between governments, academia, and industry that have gotten us to this point. Each year, new uses for current treatments are approved and new treatments are developed. With broader use of genetic testing, we will learn more about the mutations that cause various cancers and, through those investigative partnerships, work to develop treatments that block or undo those mutations.

Given the advancement in science and treatment, the good news of a downward trend in cancer mortality will likely continue, and diagnoses like metastatic melanoma that just a few years ago were death sentences may soon be treatable as chronic conditions.

New section